Similar articles for PMID: 33431379

Year	Number of Results
2006	2
2007	14
2008	29
2009	13
2010	7
2011	8
2012	3
2013	2
2014	6
2015	3
2016	2
2017	3
2018	3
2019	5
2020	6
2021	1

1

Use of Gadolinium in Individuals with Reduced Kidney Function.

Kalantari K, Swaminathan S. Kalantari K, et al. Clin J Am Soc Nephrol. 2021 Feb 8;16(2):304-306. doi: 10.2215/CJN.13950820. Epub 2021 Jan 11. Clin J Am Soc Nephrol. 2021. PMID: 33431379 No abstract available.

2

Risk of Nephrogenic Systemic Fibrosis after Exposure to Newer Gadolinium Agents [Internet].

Goldstein KM, Lunyera J, Mohottige D, Amrhein TJ, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams Jr JW, Gierisch JM. Goldstein KM, et al. Washington (DC): Department of Veterans Affairs (US); 2019 Oct. Department of Veterans Affairs (US). 2019. PMID: 32687278 Free Books & Documents. Review.

3

Nephrogenic systemic fibrosis: A 15-year retrospective study at a single tertiary care center.

Wilson J, Gleghorn K, Seigel Q, Kelly B. Wilson J, et al. J Am Acad Dermatol. 2017 Aug;77(2):235-240. doi: 10.1016/j.jaad.2017.02.003. Epub 2017 Mar 18. J Am Acad Dermatol. 2017. PMID: 28318680

4

Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.

Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Schieda N, et al. Can Assoc Radiol J. 2018 May;69(2):136-150. doi: 10.1016/j.carj.2017.11.002. Can Assoc Radiol J. 2018. PMID: 29706252 Review.

5

Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists.

Schieda N, Maralani PJ, Hurrell C, Tsampalieros AK, Hiremath S. Schieda N, et al. Can Assoc Radiol J. 2019 Aug;70(3):226-232. doi: 10.1016/j.carj.2019.04.001. Epub 2019 Jun 27. Can Assoc Radiol J. 2019. PMID: 31255393

6

Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature.

Wahba IM, Simpson EL, White K. Wahba IM, et al. Am J Transplant. 2007 Oct;7(10):2425-32. doi: 10.1111/j.1600-6143.2007.01941.x. Epub 2007 Aug 16. Am J Transplant. 2007. PMID: 17711550 Free article. Review.

7

Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.

Grobner T, Prischl FC. Grobner T, et al. Semin Dial. 2008 Mar-Apr;21(2):135-9. doi: 10.1111/j.1525-139X.2007.00406.x. Epub 2008 Jan 23. Semin Dial. 2008. PMID: 18226001 Review.

8

Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review.

Lunyera J, Mohottige D, Alexopoulos AS, Campbell H, Cameron CB, Sagalla N, Amrhein TJ, Crowley MJ, Dietch JR, Gordon AM, Kosinski AS, Cantrell S, Williams JW Jr, Gierisch JM, Ear B, Goldstein KM. Lunyera J, et al. Ann Intern Med. 2020 Jul 21;173(2):110-119. doi: 10.7326/M20-0299. Epub 2020 Jun 23. Ann Intern Med. 2020. PMID: 32568573

9

Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.

Lemy AA, del Marmol V, Kolivras A, High WA, Matos C, Laporte M, Nortier JL. Lemy AA, et al. J Am Acad Dermatol. 2010 Sep;63(3):389-99. doi: 10.1016/j.jaad.2009.10.038. Epub 2010 Jul 8. J Am Acad Dermatol. 2010. PMID: 20619488

10

Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.

Deo A, Fogel M, Cowper SE. Deo A, et al. Clin J Am Soc Nephrol. 2007 Mar;2(2):264-7. doi: 10.2215/CJN.03921106. Epub 2007 Feb 7. Clin J Am Soc Nephrol. 2007. PMID: 17699423 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed